Motixafortide

Motixafortide is a prescription medication used in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.

• Motixafortide is available under the following different brand names: Aphexda

Common side effects of Motixafortide include:

• injection-site reactions included pain, erythema, pruritus, bruising, discomfort, induration, mass, nodule, rash, swelling, and urticaria

Serious side effects of Motixafortide include:

• vomiting
• injection-site reaction
• hypersensitivity reaction
• injection site cellulitis
• hypokalemia, and hypoxia

Rare side effects of Motixafortide include:

• none

Seek medical care or call 911 at once if you have the following serious side effects:

• Severe headache, confusion, slurred speech, arm or leg weakness, trouble walking, coordination loss, unsteady, very stiff muscles, high fever, profuse sweating, or tremors;
• Serious eye symptoms such as sudden vision loss, blurred vision, tunnel vision, eye pain or swelling, or seeing halos around lights;
• Serious heart symptoms include fast, irregular, or pounding heartbeats; fluttering in the chest; shortness of breath; sudden dizziness, lightheadedness, or passing out.

This is not a complete list of side effects and other serious side effects or health problems that may occur because of the use of this drug. Call your doctor for medical advice about serious side effects or adverse reactions. You may report side effects or health problems to FDA at 1-800-FDA-1088.

Adult dosage

Injection, lyophilized powder for reconstitution

• 62 mg/single-dose vial

Multiple myeloma

Adult dosage

• Filgrastim dosing
  • Administer filgrastim 10 mcg/kg SC once a day for 4 days before the first dose of Motixafortide and on each day before each apheresis
• Premedication
  • Premedicate before each dose of motixafortide to reduce the risk of hypersensitivity and injection-site reactions
• Regimen includes
  • Administer the following approximately 30 to 60 minutes before motixafortide injection
  • Diphenhydramine (12.5 mg IV or 25 to 50 mg orally, or another H1-antihistamine), and
  • H2 blocker (eg, famotidine), and
  • Leukotriene inhibitor (eg, montelukast)
  • An analgesic medication (e.g., acetaminophen) is also recommended
• Motixafortide dosing
  • Dosing is on actual body weight
    • 1.25 mg/kg SC (over approximately 2 minutes) 10 to 14 hours before initiating the first apheresis
    • A second dose can be administered 10 to 14 hours before the third apheresis, if necessary

Dosage Considerations – Should be Given as Follows: 

• See “Dosages”